glp-1 and liver receptor agonists effective for obesity disease treatment Semaglutide improves metabolic liver disease

Based on relevance, nine abstracts were reviewed, and six full texts were selected

Progress does not require perfection

Diabetes Care 2020;43(Suppl 1):S98-S110

Moreover, depression is characterized by high prevalence of coexistence with many metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity, and brain insulin resistance observed in both of these diseases is currently considered an important factor which may lead to the manifestation of depressive symptoms [10, 11]

Notably, GLP-1RAs slow the transit time of the gastrointestinal (GI) tract and suppress appetite, which could displace nutrient intake and result in mineral and vitamin deficiencies